Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Chinea Eziefula, Farrukh T Shah & Kofi A Anie. (2022) Promoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients. Patient Preference and Adherence 16, pages 1423-1437.
Read now
Read now
Margaret Locke, Paavani S. Reddy & Sherif M. Badawy. (2022) Adherence to Iron Chelation Therapy among Adults with Thalassemia: A Systematic Review. Hemoglobin 46:4, pages 201-213.
Read now
Read now
Iman Khan, Mustafa Muhammad & Janki Patel. (2019) Deferasirox – a rarer cause of Fanconi syndrome. Journal of Community Hospital Internal Medicine Perspectives 9:4, pages 358-359.
Read now
Read now
Dijiong Wu, Xiaowen Wen, Wenbin Liu, Huijin Hu, Baodong Ye & Yuhong Zhou. (2018) Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload. Drug Design, Development and Therapy 12, pages 1081-1091.
Read now
Read now
Efthymia Vlachaki, Alexandra Agapidou, Georgios Spanos, Philippos Klonizakis, Evaggelia Vetsiou, Melahrini Mavroudi & Panagiota Boura. (2015) Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major. Hemoglobin 39:5, pages 299-304.
Read now
Read now
Z. Ozturk, G. E. Genc, A. Kupesiz, E. Kurtoglu & S. Gumuslu. (2015) Thalassemia major patients using iron chelators showed a reduced plasma thioredoxin level and reduced thioredoxin reductase activity, despite elevated oxidative stress. Free Radical Research 49:3, pages 309-316.
Read now
Read now
Mehran Karimi, Nader Cohan, Vincenzo De Sanctis, Naji S. Mallat & Ali Taher. (2014) Guidelines for Diagnosis and Management of Beta-Thalassemia Intermedia. Pediatric Hematology and Oncology 31:7, pages 583-596.
Read now
Read now
Articles from other publishers (12)
Jeremy Epah, Ilay Gülec, Stefan Winter, Johanna Dörr, Christof Geisen, Eva Haecker, Dietmar Link, Matthias Schwab, Erhard Seifried & Richard Schäfer. (2022) From Unit to Dose: A Machine Learning Approach for Precise Prediction of Hemoglobin and Iron Content in Individual Packed Red Blood Cell Units. Advanced Science 9:36.
Crossref
Crossref
U. U. Rakhmanova. (2022) Comparative characteristics of humoral immunity indicators and their relationship with chelation therapy in thalassemia. Meditsinskiy sovet = Medical Council:19, pages 162-166.
Crossref
Crossref
Jiancheng Yang, Qinghua Tang & Yuhong Zeng. (2022) Melatonin: Potential avenue for treating iron overload disorders. Ageing Research Reviews 81, pages 101717.
Crossref
Crossref
Jian Zhang, Hai Zhao, Gang Yao, Penghai Qiao, Longfei Li & Shuguang Wu. (2021) Therapeutic potential of iron chelators on osteoporosis and their cellular mechanisms. Biomedicine & Pharmacotherapy 137, pages 111380.
Crossref
Crossref
Vassilis Goulas, Alexandra Kouraklis-Symeonidis, Kyriaki Manousou, Vassileios Lazaris, George Pairas, Paraskevi Katsaouni, Eugenia Verigou, Vassiliki Labropoulou, Vassiliki Pesli, Panagiotis Kaiafas, Urania Papageorgiou & Argiris Symeonidis. (2020) A multicenter cross-sectional study of the quality of life and iron chelation treatment satisfaction of patients with transfusion-dependent β-thalassemia, in routine care settings in Western Greece. Quality of Life Research 30:2, pages 467-477.
Crossref
Crossref
Tahani Mohammed Manea, Faris Suhail Abdalhameed Khan, Renad Mohammed Alsharyufi, Kholoud Mohammed Alghamdi, Manal Khalaf Alzahrani, Fawaz Mohammed Alzubaidi, Ali Abdulaziz Alghanmi, Turki Abdullah Almahdawi, Turki Mohammed Alhasani & Nermeen Nasser Alrajhi. (2021) An Overview on Thalassemia Diagnosis and Management Approach, Literature Review. International Journal Of Pharmaceutical Research And Allied Sciences 10:2, pages 103-107.
Crossref
Crossref
Zhenbin Wei, Gaohui Yang, Yumei Huang, Peng Peng, Liling Long, Yuan Long, Xiaoping Huang, Xuemei Zhou, Yongrong Lai & Rongrong Liu. (2020) A 15‐years follow‐up of deferasirox in beta‐thalassaemia major patients with iron overload. British Journal of Haematology 191:3.
Crossref
Crossref
Marwa Zakaria & Tamer Hassan. 2020. Beta Thalassemia. Beta Thalassemia.
Mehran Karimi, Sezaneh Haghpanah, Gholamreza Bahoush, Shahla Ansari, Azita Azarkeivan, Amin Shahsavani, Asghar Bazrafshan & Ali Jangjou. (2020) Evaluation of Efficacy, Safety, and Satisfaction Taking Deferasirox Twice Daily Versus Once Daily in Patients With Transfusion-Dependent Thalassemia. Journal of Pediatric Hematology/Oncology 42:1, pages 23-26.
Crossref
Crossref
Aziz Eghbali, Pooria Shokri, Roghayeh Rahimi Afzal & Bahador Bagheri. (2019) A 1-year randomized trial of deferasirox alone versus deferasirox and deferoxamine combination for the treatment of iron overload in thalassemia major. Transfusion and Apheresis Science 58:4, pages 429-433.
Crossref
Crossref
Eitan Fibach & Eliezer A. Rachmilewitz. (2017) Pathophysiology and treatment of patients with beta-thalassemia – an update. F1000Research 6, pages 2156.
Crossref
Crossref
Gizem Esra Genc, Zeynep Ozturk, Saadet Gumuslu & Alphan Kupesiz. (2015) Mineral Levels in Thalassaemia Major Patients Using Different Iron Chelators. Biological Trace Element Research 170:1, pages 9-16.
Crossref
Crossref